Skip to content
10-Q

Quarterly Report

AVENUE THERAPEUTICS, INC. ATXI

0001437749-24-025880

← back to feed
Filed
Aug 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 7, 2024 1.43M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $4.92M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $1.78M
Stockholders Equity Q2 2024 · Jun 30, 2024 $4.76M
Stockholders Equity Q2 2024 · Dec 31, 2023 $1.58M
Current Liabilities Q2 2024 · Jun 30, 2024 $1.16M
Current Liabilities Q2 2024 · Dec 31, 2023 $1.2M
Total Liabilities Q2 2024 · Jun 30, 2024 $1.16M
Total Liabilities Q2 2024 · Dec 31, 2023 $1.2M
Total Assets Q2 2024 · Jun 30, 2024 $4.99M
Total Assets Q2 2024 · Dec 31, 2023 $1.85M
Eps Basic Q2 2024 · Jun 30, 2024 −$6.43
Eps Basic Q2 2024 · Jun 30, 2024 −$18.86
Eps Basic restated Q2 2024 · Jun 30, 2023 −$38.74
Eps Basic restated Q2 2024 · Jun 30, 2023 −$129.84
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$6.24M
Sga Expense Q2 2024 · Jun 30, 2023 $896K
Sga Expense Q2 2024 · Jun 30, 2023 $1.88M
Rd Expense Q2 2024 · Jun 30, 2023 $3.03M
Rd Expense Q2 2024 · Jun 30, 2023 $4.24M
Net Income Q2 2024 · Jun 30, 2023 −$4.01M
Net Income Q2 2024 · Jun 30, 2023 −$11.54M
Operating Income Q2 2024 · Jun 30, 2023 −$3.92M
Operating Income Q2 2024 · Jun 30, 2023 −$10.35M